Results 101 to 110 of about 665,429 (358)

Texas: demographically different [PDF]

open access: yes
Demography ...
D'Ann Petersen
core  

Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald   +74 more
wiley   +1 more source

Measurement and conceptualization of male involvement in family planning: a bibliometric analysis of Africa-based studies

open access: yesContraception and Reproductive Medicine
Background Male involvement in Family Planning (FP) is an exercise of men’s sexual and reproductive health rights. However, the measurement of male involvement has been highly inconsistent and too discretional in FP studies.
Tosin Olajide Oni   +4 more
doaj   +1 more source

Crossroads of demography [PDF]

open access: yesStanovnistvo, 2013
This paper is dedicated to the 50th anniversary of the Stanovnistvo (Population) journal, launched by the Center for demographic research in Belgrade in 1963. The anniversary is an opportunity to reflect on developments and trends in demography as a discipline, thus the paper points out certain specifics of these developments. The specifics
openaire   +3 more sources

World Religion Database [PDF]

open access: yes, 2009
This article reviews the new database released by Brill entitled World Religion Database (WRD).
Dekker, Jennifer
core  

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy